BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Omura K. Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 2008;77 Suppl 1:13-22. [PMID: 18204257 DOI: 10.1159/000111483] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, Zhang X, Pan ZZ, Wan DS, Zeng YX, Zhu XF, Zhang XS. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009;7:56. [PMID: 19583834 DOI: 10.1186/1479-5876-7-56] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 5.7] [Reference Citation Analysis]
2 Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551-1569. [PMID: 18794772 DOI: 10.3390/molecules13081551] [Cited by in Crossref: 291] [Cited by in F6Publishing: 269] [Article Influence: 20.8] [Reference Citation Analysis]
3 Lakatos G, Tulassay Z. [Antiangiogenic therapy for gastrointestinal tumors]. Orv Hetil 2008;149:2317-24. [PMID: 19042183 DOI: 10.1556/OH.2008.28496] [Reference Citation Analysis]
4 Mori R, Yoshida K, Tanahashi T, Yawata K, Kato J, Okumura N, Tsutani Y, Okada M, Oue N, Yasui W. Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Gastric Cancer 2013;16:345-54. [PMID: 22968820 DOI: 10.1007/s10120-012-0191-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yin A, Jiang Y, Zhang X, Zhao J, Luo H. Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo. European Journal of Pharmacology 2010;649:120-6. [DOI: 10.1016/j.ejphar.2010.09.040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sperling J, Schäfer T, Ziemann C, Benz-weißer A, Kollmar O, Schilling MK, Menger MD. Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis 2012;29:91-9. [DOI: 10.1007/s10585-011-9432-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
7 López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010;103:1536-41. [PMID: 20940719 DOI: 10.1038/sj.bjc.6605938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
8 Öhlén J, Wallengren Gustafsson C, Friberg F. Making Sense of Receiving Palliative Treatment: Its Significance to Palliative Cancer Care Communication and Information Provision. Cancer Nursing 2013;36:265-73. [DOI: 10.1097/ncc.0b013e31826c96d9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
9 Tolley M, Bickford L, Clare K, Johann TW. Investigations of amino acids in the ATP binding site of 5,10-methenyltetrahydrofolate synthetase. Protein J 2012;31:519-28. [PMID: 22773193 DOI: 10.1007/s10930-012-9428-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Watayo Y, Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M. Drug Monitoring During FOLFOX6 Therapy in a Rectal Cancer Patient on Chronic Hemodialysis. Japanese Journal of Clinical Oncology 2010;40:360-4. [DOI: 10.1093/jjco/hyp176] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
11 Tsoi KK, Ng SS, Leung MC, Sung JJ. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Aliment Pharmacol Ther. 2008;28:353-363. [PMID: 18638075 DOI: 10.1111/j.0269-2813.2008.03726.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
12 Cameron S, Hünerbein D, Mansuroglu T, Armbrust T, Scharf JG, Schwörer H, Füzesi L, Ramadori G. Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy. BMC Cancer 2009;9:218. [PMID: 19570230 DOI: 10.1186/1471-2407-9-218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
13 Mao Q, Zhang Y, Fu X, Xue J, Guo W, Meng M, Zhou Z, Mo X, Lu Y. A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. J Cancer Res Clin Oncol. 2013;139:211-222. [PMID: 23052691 DOI: 10.1007/s00432-012-1310-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
14 Sgambato A, Corbi M, Svelto M, Caredda E, Cittadini A. New Insights into the CD133 (Prominin-1) Expression in Mouse and Human Colon Cancer Cells. Adv Exp Med Biol. 2013;777:145-166. [PMID: 23161081 DOI: 10.1007/978-1-4614-5894-4_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yamada T, Masuda M. Emergence of TNIK inhibitors in cancer therapeutics. Cancer Sci 2017;108:818-23. [PMID: 28208209 DOI: 10.1111/cas.13203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
16 Sperling J, Schäfer T, Benz-Weißer A, Ziemann C, Scheuer C, Kollmar O, Schilling MK, Menger MD. Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases. Int J Colorectal Dis 2013;28:555-62. [PMID: 23242249 DOI: 10.1007/s00384-012-1617-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
17 Winterling J, Wasteson E, Arving C, Johansson B, Glimelius B, Nordin K. Factors associated with psychological distress and grief resolution in surviving spouses of patients with advanced gastrointestinal cancer. Support Care Cancer 2010;18:1377-84. [PMID: 19936800 DOI: 10.1007/s00520-009-0753-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
18 Xu DG, Lv W, Dai CY, Zhu FF, Xu GH, Ma ZJ, Chen Z. 2-(Pro-1-ynyl)-5-(5,6-dihydroxypenta-1,3-diynyl) thiophene induces apoptosis through reactive oxygen species-mediated JNK activation in human colon cancer SW620 cells. Anat Rec (Hoboken) 2015;298:376-85. [PMID: 25178491 DOI: 10.1002/ar.23045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
19 Azzoni C, Bottarelli L, Cecchini S, Ziccarelli A, Campanini N, Bordi C, Sarli L, Silini EM. Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features. Pathol Res Pract 2014;210:111-7. [PMID: 24332575 DOI: 10.1016/j.prp.2013.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
20 Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci 2010;101:1163-9. [PMID: 20345485 DOI: 10.1111/j.1349-7006.2010.01504.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
21 Sawa M, Masuda M, Yamada T. Targeting the Wnt signaling pathway in colorectal cancer. Expert Opin Ther Targets. 2016;20:419-429. [PMID: 26439805 DOI: 10.1517/14728222.2016.1098619] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
22 Cao B, Li ST, Li Z, Deng WL. Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. Chin J Integr Med 2011;17:593-9. [PMID: 21826593 DOI: 10.1007/s11655-011-0822-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
23 Cui HG, Cao XF. Surgery-predominant combined treatment for colorectal cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(16): 1774-1780 [DOI: 10.11569/wcjd.v16.i16.1774] [Cited by in F6Publishing: 1] [Reference Citation Analysis]